Unknown PHASE2 INTERVENTIONAL NCT00003160

Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum

A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Patients With Taxol/Platinum-Refractory Stage III and IV Ovarian Cancer

Sponsor: Theradex

Conditions Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer

Interventions paclitaxel

Updated 6 times since 2017 Last updated: Apr 19, 2011 Started: Sep 30, 1997

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Fallopian Tube Cancer and Ovarian Cancer, this trial is ongoing. The trial is conducted by Theradex and has accumulated 6 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Sep 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theradex

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Amarillo, United States , Charlotte, United States , Cincinnati, United States , Cleveland, United States , Decatur, United States , Fayetteville, United States , Harrisburg, United States , Mobile, United States and 8 more locations